Predicted protein targets (top 17)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 5/20 | 0.52 |
| ▸ | MAPT | P10636 | 4/20 | 0.52 |
| ▸ | MEN1 | O00255 | 2/20 | 0.52 |
| ▸ | KMT2A | Q03164 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 2/20 | 0.49 |
| ▸ | KDM4E | B2RXH2 | 2/20 | 0.49 |
| ▸ | LMNA | P02545 | 1/20 | 0.49 |
| ▸ | ESRRA | P11474 | 2/20 | 0.47 |
| ▸ | GAA | P10253 | 3/20 | 0.46 |
| ▸ | AURKA | O14965 | 1/20 | 0.45 |
| ▸ | AURKB | Q96GD4 | 1/20 | 0.45 |
| ▸ | SMN1; SMN2 | Q16637 | 3/20 | 0.44 |
| ▸ | KDR | P35968 | 1/20 | 0.43 |
| ▸ | JAK2 | O60674 | 2/20 | 0.43 |
| ▸ | PKM | P14618 | 1/20 | 0.41 |
| ▸ | MAPK1 | P28482 | 1/20 | 0.41 |
| ▸ | L3MBTL1 | Q9Y468 | 1/20 | 0.41 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL13552954 | 0.96 | GAA (0.47) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL13552974 | 0.91 | ESRRA (0.44) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL14707412 | 0.88 | KDR (0.43) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL14707420 | 0.85 | KMT2A (0.51) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13044592 | 0.84 | CACNA1B (0.48) | ALDH1A1MEN1KMT2APOLBESRRA | |
| SCHEMBL13043661 | 0.84 | USP28 (0.49) | MAPTMEN1KMT2AKDM4EESRRA | |
| SCHEMBL13552972 | 0.83 | ALDH1A1 (0.54) | ALDH1A1MAPTMEN1KMT2APOLB | |
| SCHEMBL13552952 | 0.83 | KMT2A (0.45) | ALDH1A1MAPTMEN1KMT2ALMNA | |
| SCHEMBL13552736 | 0.83 | ALDH1A1 (0.49) | ALDH1A1MAPTMEN1KMT2AKDM4E | |
| SCHEMBL13552957 | 0.83 | MEN1 (0.47) | ALDH1A1MAPTMEN1KMT2AKDM4E |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 8 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-9345699-B2 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | NANTBIOSCIENCE, INC. (US) | 2016-05-24 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2014-03-13 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | ABRAXIS BIOSCIENCE, LLC (US) | 2013-02-21 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | CALIFORNIA CAPITAL EQUITY, LLC (US) | 2012-10-25 | — | — | US | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (3 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20130045240-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | ALDH1A1 1730/4885MAPT 427/4885MEN1 1016/4885 |
| US-20120270858-A1 | Isoquinoline, quinoline, and quinazoline derivatives as inhibitors of hedgehog signaling | SHH, GLI1, SMO | ALDH1A1 2485/4885MAPT 2831/4885MEN1 1456/4885 |
| US-20140072630-A1 | COMBINATION THERAPY WITH NANOPARTICLE COMPOSITIONS OF TAXANE AND HEDGEHOG INHIBITORS | SHH, GLI1, SMO | ALDH1A1 1730/4885MAPT 427/4885MEN1 1016/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.